Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) insider Gwenn Hansen sold 3,437 shares of Nurix Therapeutics stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $24.30, for a total value of $83,519.10. Following the transaction, the insider now directly owns 50,670 shares in the company, valued at approximately $1,231,281. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Nurix Therapeutics Trading Down 4.5 %
Shares of NASDAQ NRIX traded down $1.13 during trading hours on Wednesday, hitting $24.07. 761,824 shares of the company traded hands, compared to its average volume of 885,869. The stock has a market capitalization of $1.71 billion, a price-to-earnings ratio of -8.66 and a beta of 2.22. The company’s 50 day moving average price is $24.18 and its 200 day moving average price is $20.14. Nurix Therapeutics, Inc. has a 12 month low of $4.96 and a 12 month high of $27.60.
Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) last released its earnings results on Friday, October 11th. The company reported ($0.67) earnings per share for the quarter, meeting the consensus estimate of ($0.67). The firm had revenue of $12.59 million for the quarter, compared to the consensus estimate of $13.85 million. Nurix Therapeutics had a negative return on equity of 63.39% and a negative net margin of 313.65%. Equities analysts anticipate that Nurix Therapeutics, Inc. will post -2.84 EPS for the current year.
Wall Street Analyst Weigh In
Check Out Our Latest Analysis on NRIX
Hedge Funds Weigh In On Nurix Therapeutics
Several hedge funds have recently bought and sold shares of NRIX. Amalgamated Bank grew its position in Nurix Therapeutics by 30.6% in the 3rd quarter. Amalgamated Bank now owns 2,182 shares of the company’s stock valued at $49,000 after acquiring an additional 511 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in Nurix Therapeutics by 31.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,330 shares of the company’s stock valued at $54,000 after acquiring an additional 559 shares during the last quarter. GAMMA Investing LLC grew its position in Nurix Therapeutics by 299.8% in the 2nd quarter. GAMMA Investing LLC now owns 4,566 shares of the company’s stock valued at $95,000 after acquiring an additional 3,424 shares during the last quarter. International Assets Investment Management LLC grew its position in Nurix Therapeutics by 1,098.4% in the 3rd quarter. International Assets Investment Management LLC now owns 4,494 shares of the company’s stock valued at $101,000 after acquiring an additional 4,119 shares during the last quarter. Finally, EntryPoint Capital LLC bought a new position in Nurix Therapeutics in the 1st quarter valued at $123,000.
Nurix Therapeutics Company Profile
Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.
Read More
- Five stocks we like better than Nurix Therapeutics
- How to Read Stock Charts for Beginners
- Boeing: Why Analysts Think Now’s The Time To Be Brave
- Stock Market Sectors: What Are They and How Many Are There?
- Advanced Micro Devices is Building Momentum with AI: Buy the Dip
- How to Use the MarketBeat Excel Dividend Calculator
- Can Evolv Stock Recover From Its Massive Self-Inflicted Drop?
Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.